What is Gaize?
Gaize operates at the intersection of biometric technology and workplace safety, providing an automated platform designed to detect impairment from marijuana and other substances. The company's core value proposition lies in its ability to deliver real-time, defensible results with over 98% accuracy, effectively bridging the gap between traditional, slow-turnaround drug testing and the immediate needs of modern enterprise operations. By offering a non-invasive, objective assessment tool, Gaize enables organizations to maintain rigorous safety standards while fostering a fair and transparent environment for their workforce. Their client base spans from Fortune 500 corporations to smaller enterprises, all of whom utilize the platform to mitigate risk and ensure operational continuity in high-stakes environments.
How much funding has Gaize raised?
Gaize has raised a total of $1.2M across 1 funding round:
Angel/Seed
$1.2M
Angel/Seed (2022): $1.2M with participation from Fritz Lanman
Key Investors in Gaize
Fritz Lanman
An experienced angel investor and executive known for supporting high-growth technology ventures and innovative software platforms.
What's next for Gaize?
With this major strategic investment, Gaize is well-positioned to scale its operations and expand its footprint within the enterprise sector. The company is expected to focus on enhancing its algorithmic capabilities and broadening its market reach, particularly as regulatory landscapes regarding substance use continue to evolve. Future growth will likely center on integrating their ocular testing platform into existing human resources and safety management workflows, further cementing their role as a standard-bearer for workplace impairment detection. As the firm moves beyond its initial development phase, the focus will shift toward long-term adoption and the establishment of new industry benchmarks for safety compliance.
See full Gaize company page
